ReviewChembiochem : a European journal of chemical biology2026
Advances in Cyclic Peptides Targeting G Protein-Coupled Receptors.
Review in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Peptide-responsive G protein-coupled receptors (GPCRs) often recognize endogenous peptide ligands through extended receptor interfaces, providing opportunities for peptide-based ligands to engage receptor contacts that conventional small molecules struggle to access effectively. In this context, cyclic peptides are more than stabilized peptide analogs: their constrained topologies can preorganize key pharmacophoric elements, support engagement with extended orthosteric or allosteric receptor interfaces, and allow precise tuning of selectivity and signaling output. In this review, we discuss cyclic peptides targeting peptide-responsive GPCRs through three connected dimensions: natural macrocyclic ligands and scaffolds, chemical strategies for topological and functional optimization, and emerging discovery platforms for GPCR-active macrocycles. Specifically, we examine how endogenous cyclic peptides, venom-derived peptides, plant cyclotides, and microbial macrocycles provide structurally defined templates for probing GPCR recognition, and how engineering approaches, including bridge replacement, conformational locking, residue modification, and half-life extension, have expanded their utility as both bioactive ligands and molecular probes. We further highlight discovery technologies (e.g., mRNA display, phage display, cell-based screening, and structure- and computation-guided design) that are advancing the discovery and optimization of macrocycles with improved receptor specificity and pharmacological properties. Together, these advances position cyclic peptides as a topology-guided molecular strategy for dissecting peptide-GPCR recognition and developing next-generation therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.